Printed from https://ideas.repec.org/s/ohe/grafun.html
Content
2024
- 002484 Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During Pregnancy
by Nadine Henderson;George Bray;Chris Skedgel
2023
- 002482 2022 OHE Annual Report to the Charity Commission
by Office of Health Economics
2022
- 002472 2021 OHE Annual Report to the Charity Commission
by Mireia Jofre-Bonet
2021
- 002323 Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
by Patricia Cubi-Molla;David Mott;Nadine Henderson;Martina Garau;Bernarda Zamora;Mendel Grobler
2020
- 002308 Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?
by Chris Sampson;David Parkin;Nancy Devlin - 002298 Cornerstones of “Fair” Drug Coverage: Appropriate Cost - Sharing and Utilization Management Policies for Pharmaceuticals
by Steven D Pearson;Maria Lowe;Celia S. Segal;Chris Henshall;Adrian Towse
2019
- 002187 The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
by Niklas Wallin-Bernhardsson;Peter Lindgren;Mikel Berdud;Bernarda Zamora;Adrian Towse - 002184 Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
by Koonal Shah;Juan Manuel Ramos-Goñi;Nancy Devlin;Oliver Rivero-Arias - 002154 The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
by Simon Brassel;Olga Rozanova;Adrian Towse - 002150 The Future of Global Health Procurement: Issues around Pricing Transparency
by Mikel Berdud;Adrian Towse;Kalipso Chalkidou;Emma Dean;Jimena Ferraro;Lou Garrison;Cassandra Nemzoff - 002142 Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
by Karla Hernandez-Villafuerte;Yan Feng;David Parkin;Nancy Devlin;Bernarda Zamora;Adrian Towse - 002094 Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA
by Nancy Devlin;Paula Lorgelly;Mike Herdman
2018
- 002044 Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research
by Bernarda Zamora;Adrian Towse;Karla Hernandez-Villafuerte - 002040 R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
by Mikel Berdud;Martina Garau;Margherita Neri;Phill O’Neill;Chris Sampson;Adrian Towse - 002036 Establishing a Reasonable Price for an Orphan Drug
by Michael F. Drummond;Mikel Berdud;Adrian Towse - 001984 New Methods for Analysing the Distribution of EQ-5D Observations
by David Parkin;Yan Feng;Andrew Bateman;Mike Herdman;Nancy Devlin;Bernarda Zamora
2017
- 001871 Why Do Immigrants Report Lower Life Satisfaction?
by Firat Yaman;Patricia Cubi-Molla - 001798 What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?
by Nancy Devlin;Koonal Shah;Ken Buckingham
2016
- 001777 An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’
by Aurea Duran;Nancy Devlin;Phill O’Neill;Amanda Cole - 001764 Uncertainty and Risk in HTA Decision Making
by Paul Barnsley;Adrian Towse;Patricia Cubi-Molla - 001756 The Distribution of the EQ-5D-5L Index in Patient Populations
by Bernarda Zamora;Yan Feng;Nancy Devlin;Andrew Bateman;David Parkin - 001679 New Methods for Modelling EQ-5D-5L Value Sets: An Application to English Data
by Yan Feng;Nancy Devlin;Koonal Shah;Brendan Mulhern;Ben van Hout - 001678 Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England
by Nancy Devlin;Koonal Shah;Yan Feng;Berndan Mulhern;Ben Van Hout
2015
- 001669 Model of Behaviour within Fuzzy Budget Constraints
by Office of Health Economics - 001632 Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
by Michele Pistollato
2014
- 000517 Opportunity Costs of Implementing NICE Decisions in NHS Wales
by Sarah Karlsberg-Schaffer;Jon Sussex;Dyfrig Hughs;Nancy Devlin
2013
- 000037 Exploring the link between health and wealth in decision making
by Koonal Shah;Priya Sharma;Martina Garau;Adrian Towse
2012
- 000126 Understanding Social Preferences Regarding the Prioritisation of Treatments Addressing Unmet Need and Severity
by Koonal Shah;Nancy Devlin
2011
- 000175 The Effect of an Increase in the Rate of Payment on General Practitioner's Intrinsic and Extrinsic Motivation
by Yan Feng;Shelley Farrar;Matt Sutton;Ada May - 000172 Valuing Health at the End of Life: An Exploratory Preference Elicitation Study
by Koonal Shah;Aki Tsuchiya;Allan Wailoo